(PBH) Prestige Brand Holdings - Ratings and Ratios
Analgesic, Diaper, Throat, Eye, Wart, Ear
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 23.7% |
| Value at Risk 5%th | 38.2% |
| Relative Tail Risk | -1.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.21 |
| Alpha | -37.53 |
| CAGR/Max DD | 0.00 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.433 |
| Beta | 0.477 |
| Beta Downside | 0.371 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.49% |
| Mean DD | 10.36% |
| Median DD | 9.08% |
Description: PBH Prestige Brand Holdings November 09, 2025
Prestige Consumer Healthcare Inc. (NYSE: PBH) manufactures and markets a broad portfolio of over-the-counter (OTC) health and personal-care products across North America, Australia, and other international markets. The business is split into two segments-North American OTC Healthcare and International OTC Healthcare-and includes well-known brands such as BC & Goody’s analgesics, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Luden’s, Monistat, Nix, Summer’s Eve, TheraTears, Fess, and Hydralyte. Products are sold through mass merchandisers, drug and grocery chains, dollar-stores, convenience outlets, club stores, and e-commerce platforms.
Key recent metrics show PBH generated roughly $1.3 billion in net sales for FY 2023, with an adjusted EBITDA margin of about 12 % and a dividend yield near 3 %. E-commerce sales have accelerated, growing roughly 15 % year-over-year, while the broader U.S. OTC market-driven by an aging population and a shift toward self-care-remains a $35 billion opportunity. Inflationary pressure on raw-material costs and the company’s “private-label” strategy to acquire niche brands are material risk factors that could affect future margins.
For a deeper, data-driven look at PBH’s valuation and how it stacks up against peers, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (200.8m TTM) > 0 and > 6% of Revenue (6% = 66.6m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -0.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.66% (prev 24.66%; Δ 8.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 263.4m > Net Income 200.8m (YES >=105%, WARN >=100%) |
| Net Debt (921.9m) to EBITDA (356.9m) ratio: 2.58 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.3m) change vs 12m ago -1.47% (target <= -2.0% for YES) |
| Gross Margin 56.36% (prev 55.22%; Δ 1.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.87% (prev 33.48%; Δ -0.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.71 (EBITDA TTM 356.9m / Interest Expense TTM 42.5m) >= 6 (WARN >= 3) |
Altman Z'' 3.95
| (A) 0.11 = (Total Current Assets 497.4m - Total Current Liabilities 134.6m) / Total Assets 3.44b |
| (B) 0.48 = Retained Earnings (Balance) 1.65b / Total Assets 3.44b |
| (C) 0.10 = EBIT TTM 327.5m / Avg Total Assets 3.38b |
| (D) 1.00 = Book Value of Equity 1.61b / Total Liabilities 1.62b |
| Total Rating: 3.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.11
| 1. Piotroski 6.0pt |
| 2. FCF Yield 6.64% |
| 3. FCF Margin 23.00% |
| 4. Debt/Equity 0.57 |
| 5. Debt/Ebitda 2.58 |
| 6. ROIC - WACC (= 1.21)% |
| 7. RoE 11.00% |
| 8. Rev. Trend -5.09% |
| 9. EPS Trend 15.11% |
What is the price of PBH shares?
Over the past week, the price has changed by +1.49%, over one month by +1.45%, over three months by -7.55% and over the past year by -26.97%.
Is PBH a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the PBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 78 | 28.2% |
| Analysts Target Price | 78 | 28.2% |
| ValueRay Target Price | 54.9 | -9.8% |
PBH Fundamental Data Overview November 25, 2025
P/E Trailing = 14.7079
P/E Forward = 13.0378
P/S = 2.6334
P/B = 1.5656
P/EG = 2.1017
Beta = 0.388
Revenue TTM = 1.11b USD
EBIT TTM = 327.5m USD
EBITDA TTM = 356.9m USD
Long Term Debt = 993.1m USD (from longTermDebt, last quarter)
Short Term Debt = 8.62m USD (from shortTermDebt, last quarter)
Debt = 1.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 921.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.85b USD (2.92b + Debt 1.04b - CCE 119.1m)
Interest Coverage Ratio = 7.71 (Ebit TTM 327.5m / Interest Expense TTM 42.5m)
FCF Yield = 6.64% (FCF TTM 255.5m / Enterprise Value 3.85b)
FCF Margin = 23.00% (FCF TTM 255.5m / Revenue TTM 1.11b)
Net Margin = 18.08% (Net Income TTM 200.8m / Revenue TTM 1.11b)
Gross Margin = 56.36% ((Revenue TTM 1.11b - Cost of Revenue TTM 484.7m) / Revenue TTM)
Gross Margin QoQ = 56.21% (prev 54.16%)
Tobins Q-Ratio = 1.12 (Enterprise Value 3.85b / Total Assets 3.44b)
Interest Expense / Debt = 0.96% (Interest Expense 10.0m / Debt 1.04b)
Taxrate = 38.94% (26.9m / 69.1m)
NOPAT = 199.9m (EBIT 327.5m * (1 - 38.94%))
Current Ratio = 3.70 (Total Current Assets 497.4m / Total Current Liabilities 134.6m)
Debt / Equity = 0.57 (Debt 1.04b / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 2.58 (Net Debt 921.9m / EBITDA 356.9m)
Debt / FCF = 3.61 (Net Debt 921.9m / FCF TTM 255.5m)
Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.83% (Net Income 200.8m / Total Assets 3.44b)
RoE = 11.00% (Net Income TTM 200.8m / Total Stockholder Equity 1.83b)
RoCE = 11.62% (EBIT 327.5m / Capital Employed (Equity 1.83b + L.T.Debt 993.1m))
RoIC = 7.09% (NOPAT 199.9m / Invested Capital 2.82b)
WACC = 5.88% (E(2.92b)/V(3.97b) * Re(7.77%) + D(1.04b)/V(3.97b) * Rd(0.96%) * (1-Tc(0.39)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.86%
[DCF Debug] Terminal Value 78.63% ; FCFE base≈255.1m ; Y1≈261.2m ; Y5≈290.6m
Fair Price DCF = 106.4 (DCF Value 5.12b / Shares Outstanding 48.1m; 5y FCF grow 2.28% → 3.0% )
EPS Correlation: 15.11 | EPS CAGR: -3.68% | SUE: -1.59 | # QB: 0
Revenue Correlation: -5.09 | Revenue CAGR: -0.03% | SUE: 2.42 | # QB: 1
EPS current Year (2026-03-31): EPS=4.55 | Chg30d=+0.022 | Revisions Net=+2 | Growth EPS=+0.6% | Growth Revenue=-2.7%
EPS next Year (2027-03-31): EPS=4.83 | Chg30d=+0.055 | Revisions Net=+3 | Growth EPS=+6.3% | Growth Revenue=+2.6%
Additional Sources for PBH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle